Evidence supporting an altered immune response in ASD

Immunology Letters

Volumn 163, Issue 1, 2015, Pages 49-55

  Mead, Jennifer ^a   Ashwood, Paul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism spectrum disorders; Behavior; Cytokines; Immune; Innate immunity; Monocytes

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CD20 ANTIGEN; CD38 ANTIGEN; CELECOXIB; CXCL9 CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; EOTAXIN; EOTAXIN 2; FAS ANTIGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PREDNISONE; RISPERIDONE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; AUTOANTIBODY;

ARTICLE; AUTISM; BEHAVIOR CHANGE; CELL PROLIFERATION; CELLULAR IMMUNITY; COMMUNICATION DISORDER; COMORBIDITY; COMPULSION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIGESTIVE SYSTEM INFLAMMATION; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; MONOCYTE; NATURAL KILLER CELL; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; SOCIAL INTERACTION; SYNAPSE; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY; MOUSE; NEUROLOGIC DISEASE; PATHOLOGY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; KILLER CELLS, NATURAL; MICE; T-LYMPHOCYTES;

EID: 84913529177     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.11.006     Document Type: Review

References (100)

1. Baio J. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR 2014, 63:1-21.
2. Ashwood P., Wills S., Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006, 80:1-15.
3. Akshoomoff N., Pierce K., Courchesne E. The neurobiological basis of autism from a developmental perspective. Dev Psychopathol 2002, 14:613-634.
4. Amaral D., Schumann C., Nordahl C. Neuroanatomy of autism. Trends Neurosci 2008, 31:137-145.
5. Breece E., Paciotti B., Nordahl C., Ozonoff S., Van de Water J., Rogers S., et al. Myeloid dendritic cells frequencies are increased in children with autism spectrum disorder and associated with amygdala volume and repetitive behaviors. Brain Behav Immun 2013, 31:69-75.
6. Barnea-Goraly N., Kwon H., Menon V., Eliez S., Lotspeich L., Reiss A. White matter structure in autism preliminary evidence from diffusion tensor imaging. Biol Psychiatry 2004, 55:323-326.
7. Viscidi E., Johnson A., Spence S., Buka S., Morrow E., Triche E. The association between epilepsy and autism symptoms and maladaptive behaviors in children with autism spectrum disorder. Autism 2013, 0:1-11.
8. Maski K., Jeste S., Spence S. Common neurological co-morbidities in autism spectrum disorders. Curr Opin Pediatr 2011, 23:609-615.
9. Molloy C., Manning-Courtney P. Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism 2003, 7:165-171.
10. Nikolov R., Bearss K., Lettinga J., Erickson C., Rodowski M., Aman M., et al. Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. J Autism Dev Disord 2009, 39:405-413.
11. Bohm H., Stewart M. Brief report on the concordance percentages for autistic spectrum disorder of twins. J Autism Dev Disord 2009, 39:806-808.
12. Campbell D., Sutcliffe J., Ebert P., Militerni R., Bravaccio C., Trillo S., et al. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci USA 2006, 103:16834-16839.
13. Warren R., Odell J., Warren W., Burger R., Maciulis A., Daniels W., et al. Strong association of the third hypervariable region of HLA-DR beta 1 with autism. J Neuroimmunol 1996, 67:97-102.
14. Lee L., Zachary A., Leffell M., Newschaffer C., Matteson K., Tyler J., et al. HLA-DR4 in families with autism. Pediatr Neurol 2006, 35:303-307.
15. Johnson W., Buyske S., Mars A., Sreenath M., Stenroos E., Williams T., et al. HLA-DR4 as a risk allele for autism acting in mothers of probands possibly during pregnancy. Arch Pediatr Adolesc Med 2009, 163:542-546.
16. Hallmayer J., Cleveland S., Torres A., Phillips J., Cohen B., Torigue T., et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011, 68:1095-1102.
17. Stromland K., Nordin V., Miller M., Akerstrom B., Gillberg C. Autism in a thalidomide embryopathy a population study. Dev Med Child Neuro 1994, 36:351-356.
18. Patterson P.H. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 2009, 204:313-321.
19. Atladottir H., Thorsen P., Ostergaard L., Schendel D., Lemcke S., Abdallah M., et al. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J Autism Dev Disord 2010, 40:1423-1430.
20. Lee L., Newschaffer C., Lessler J., Lee B., Shah R., Zimmerman A. Variation in season of birth in singleton and multiple births concordant for autism spectrum disorders. Paediatr Perinat Epidemiol 2008, 22:172-179.
21. Zerbo O., Losif A., Walker C., Ozonoff S., Hansen R., Hertz-Picciotto I. Is maternal influenza or fever during pregnancy associated with autism or developmental delays? Results from the CHARGE (Childhood Autism Risks from Genetics and Environment) study. J Autism Dev Disord 2013, 43:25-33.
22. Dunzendorfer S., Kaser A., Meierhofer C., Tilg H., Wiedermann C. Cutting edge peripheral neuropeptides attract immature and arrest mature blood-derived dendritic cells. J Immunol 2001, 166:2167-2172.
23. Chavarria A., Cardenas G. Neuronal influence behind the central nervous system regulation of the immune cells. Front Integr Neurosci 2013, 7:64.
24. Brynckikh A., Warren T., Zhu J., Kipnis J. Adaptive immunity affects learning behavior in mice. Brain Behav Immun 2008, 22:861-869.
25. Dantzer R. Cytokine-induced sickness behavior: where do we stand. Brain Behav Immun 2001, 15:7-24.
26. Stevens B., Allen N.J., Vazquez L.E., Howell G.R., Christopherson K.S., Nouri N., et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007, 131:1164-1178.
27. Perry V., O'Connor V. C1q the perfect compliment for a synaptic feast. Nat Rev Neurosci 2008, 9:807-811.
28. Goddard C., Butts D., Shatz C. Regulation of CNS synapses by neuronal MHC class I. Proc Natl Acad Sci 2007, 104:6828-6833.
29. Ribic A., Zhang M., Schlumbohm C., Matz-Rensing K., Uchanska-Ziegler B., Flügge G., et al. Neuronal MHC class I molecules are involved in excitatory synaptic transmission at the hippocampal mossy fiber synapses of marmoset monkeys. Cell Mol Neurobiol 2010, 30:827-839.
30. McConnell M., Huang Y., Datwanti A., Shatz C. H2-Kb and H2-Db regulate cerebellar long-term depression and limit motor learning. Proc Natl Acad Sci 2009, 106:6784-6789.
31. Shatz C.J. MHC class I: an unexpected role in neuronal plasticity. Neuron 2009, 64:40-45.
32. Nawa H., Takei N. Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 2006, 56:2-13.
33. Jarskog F., Xiao H., Wilkie M., Lauder J., Gilmore J. Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci 1997, 15:6005.
34. Ross R., Allan S., Rothwell N., Verkhratsky A. A dual role for interleukin-1 in LTP in mouse hippocampal slices. J Neuroimmunol 2003, 144:61-67.
35. de la Mano A., Gato A., Alonso M.I., Carnicero E., Martin C., Moro J.A. Role of interleukin-1beta in the control of neuroepithelial proliferation and differentiation of the spinal cord during development. Cytokine 2007, 37:128-137.
36. Goines P., Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment. Neurotoxicol Teratol 2013, 36:67-81.
37. Gadient R., Otten U. Expression of interleukin-6 and interleukin-6 receptor (IL-6R) mRNAs in rat brain during postnatal development. Brain Res 1994, 637:10-14.
38. Hang C., Shi J., Tian J., Li J., Wu W., Yin H. Effect of systemic LPS injection on cortical NF-κB activity and inflammatory response following traumatic brain injury in rats. Brain Res 2004, 1026:23-32.
39. Corbin J., Kelly D., Rath E., Baerwald K., Suzuki K., Popko B. Targeted CNS expression of interferon-y in transgenic mice leads to hypomyelination reactive gliosis and abnormal cerebellar development. Mol Cell Neurosci 1996, 7:354-370.
40. Kunis G., Baruch K., Rosenzweig N., Kertser A., Miller O., Berkutzki T., et al. IFN-gamma-dependent activation of the brain's choroid plexus for CNS immune surveillance and repair. Brain 2013, 136:3427-3440.
41. Garg S., Kipnis J., Banerjee R. IFN-γ and IL-4 differentially shape metabolic responses and neuroprotective phenotype of astrocytes. J Neurochem 2009, 108:1155-1166.
42. You Z., Luo C., Zhang W., Chen Y., He J., Zhao Q., et al. Pro- and anti-inflammatory cytokines expression in rat's brain and spleen exposed to chronic mild stress: involvement in depression. Behav Brain Res 2011, 225:135-141.
43. Tian L., Ma L., Kaarela T., Li Z. Neuroimmune crosstalk in the central nervous system and its significance for neurological diseases. J Neuroinflamm 2012, 9:155.
44. Streit W. Microglia and macrophages in the developing CNS. Neurotoxicology 2001, 22:619-624.
45. Schwartz M., Kipnis J., Rivest S., Prat A. How do immune cells support and shape the brain in health, disease, and aging. J Neurosci 2013, 33:17587-17596.
46. Stubbs E., Crawford M. Depressed lymphocyte responsiveness in autistic children. J Autism Child Schizophr 1977, 7:49-55.
47. Ashwood P., Kwong C., Hansen R., Hertz-Picciotto I., Croen L., Krakowiak P., et al. Brief report: plasma leptin levels are elevated in autism: association with early onset phenotype. J Autism Dev Disord 2008, 38:169-175.
48. Atladottir H., Pedersen M., Thorsen P., Mortensen P., Deleuran B., Eaton W., et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 2009, 124:687-694.
49. Croen L., Grether J., Yoshida C., Odouli R., Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders. Arch Pediatr Adolesc Med 2005, 159:151-157.
50. Braunschweig D., Ashwood P., Krakowiak P., Hertz-Picciotto I., Hansen R., Croen L., et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology 2008, 29:226-231.
51. Braunschweig D., Van de Water J. Maternal autoantibodies in autism. Arch Neurol 2012, 69:693-699.
52. Croen L., Braunschweig D., Haapanen L., Yoshida C., Fireman B., Grether J., et al. Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study. Biol Psychiatry 2008, 64:583-588.
53. Singer H., Morris C., Gause C., Gillin P., Crawford S., Zimmerman A. Antibodies against fetal brain in sera of mothers with autistic children. J Neuroimmunol 2008, 194:165-172.
54. Nordahl C., Braunschweig D., Iosif A., Lee A., Rogers S., Ashwood P., et al. Maternal autoantibodies are associated with abnormal brain enlargement in a subgroup of children with autism spectrum disorder. Brain Behav Immun 2013, 30:61-65.
55. Bauman M., Losif A-M., Ashwood P., Braunschweig D., Lee A., Schumann C., et al. Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. Transl Psychiatry 2013, 3:e278.
56. Martin L., Ashwood P., Braunschweig D., Cabanlit M., Van de Water J., Amaral D. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun 2008, 22:806-816.
57. Heuer L., Braunschweig D., Ashwood P., Van de Water J., Campbell D. Association of a MET genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression. Transl Psychiatry 2011, 1:e48.
58. Braunschweig D., Krakowiak P., Duncanson P., Boyce R., Hansen R., Ashwood P., et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Transl Psychiatry 2013, 3:e277.
59. Enstrom A., Van de Water J., Ashwood P. Autoimmunity in autism. Curr Opin Investig Drugs 2009, 10:463-473.
60. Gesundheit B., Rosenzweig J., Naor D., Lerer B., Zachor D., Prochazka V., et al. Immunological and autoimmune considerations of autism spectrum disorders. J Autoimmun 2013, 44:1-7.
61. Cabanlit M., Wills S., Goines P., Ashwood P., Van de Water J. Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann N Y Acad Sci 2007, 1107:92-103.
62. Enstrom A., Krakowiak P., Onore C., Pessah I., Hertz-Picciotto I., Hansen R., et al. Increased IgG4 levels in children with autism disorder. Brain Behav Immun 2009, 23:389-395.
63. Croonenberghs J., Wauters A., Devreese K., Verkerk R., Scharpe S., Bosmans E., et al. Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med 2002, 32:1457-1463.
64. Heuer L., Ashwood P., Schauer J., Goines P., Krakowiak P., Hertz-Picciotto I., et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res 2008, 1:275-283.
65. Ashwood P., Krakowiak P., Hertz-Picciotto I., Hansen R., Pessah I., Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 2011, 25:40-45.
66. Ricci S., Businaro R., Ippoliti F., Lo Vasco V., Massoni F., Onofri E., et al. Altered cytokine and BDNF levels in autism spectrum disorder. Neurotox Res 2013, 24:491-501.
67. Sweeten T., Posey D., McDougle C. High blood monocyte counts and neopterin levels in children with autistic disorder. Am J Psychiatry 2003, 160:1691-1693.
68. Enstrom A., Onore C., Van de Water J., Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun 2010, 24:64-71.
69. Ashwood P., Corbett B., Kantor A., Schulman H., Van de Water J., Amaral D. In search of cellular immunophenotypes in the blood of children with autism. PLoS ONE 2011, 6:e19299.
70. Singh V. Plasma increase of interleukin-12 and interferon-gamma pathological significance in autism. J Neuroimmunol 1996, 66:143-145.
71. Li X., Chauhn A., Shiekh A., Patil S., Chauhn V., Li X., et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009, 207:111-116.
72. Croonenberghs J., Bosmans E., Deboutte D., Kenis G., Maes M. Activation of the inflammatory response system in autism. Neuropsychobiology 2002, 45:1-6.
73. Ashwood P., Krakowiak P., Hertz-Picciotto I., Hansen R., Pessah I., Van de Water J. Altered T cell responses in children with autism. Brain Behav Immun 2011, 25:840-849.
74. Gupta S., Aggarwal S., Rashanravan B., Lee T. TH1 and TH2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol 1998, 85:106-109.
75. Saresalla M., Marventano I., Guerini F., Mancuso R., Ceresa L., Zanzottera M., et al. An autistic endophenotype results in complex immune dysfunction in healthy siblings of autistic children. Biol Psychiatry 2009, 66:978-984.
76. Enstrom A., Lit L., Onore C., Gregg J., Hansen R., Pessah I., et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun 2009, 23:124-133.
77. Gregg J., Lit L., Baron C., Hertz-Picciotto I., Walker W., Davis R., et al. Gene expression changes in children with autism. Genomics 2008, 91:22-29.
78. Warren R., Foster A., Margaretten N. Reduced natural killer cell activity in autism. J Am Acad Child Adolesc Psychiatry 1987, 26:333-335.
79. Torres A., Westover J., Gibbons C., Johnson R., Ward D. Activating killer-cell immunoglobulin-like receptors (KIR) and their cognate HLA ligands are significantly increased in autism. Brain Behav Immun 2012, 26:1122-1127.
80. Guerini F., Bolognesi E., Chiappedi M., Manca S., Ghezzo A., Agliardi C., et al. Activating KIR molecules and their cognate ligands prevail in children with a diagnosis of ASD and in their mothers. Brain Behav Immun 2014, 36:54-60.
81. Goines P., Croen L., Braunschweig D., Yoshida C., Grether J., Hansen R., et al. Increased midgestational IFN-gamma, IL-4 and IL-5 in women bearing a child with autism: a case-control study. Mol Autism 2011, 2:13.
82. Denney D., Frei B. Lymphocyte subsets and interleukin-2 receptors in autistic children. J Autism Dev Disord 1996, 26:87-97.
83. Onore C., Enstrom A., Krakowiak P., Hertz-Picciotto I., Hansen R., Van de Water J., et al. Decreased cellular IL-12 but not IL-17 production in children with autism spectrum disorders. J Neuroimmunol 2009, 216:126-129.
84. Al-Ayadhi L., Mostafa G. Elevated serum levels of interleukin-17a in children with autism. J Neuroinflamm 2012, 9.
85. Ashwood P., Enstrom A., Krakowiak P., Hertz-Picciotto I., Hansen R., Croen L., et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 2008, 204:149-153.
86. Okada K., Hashimoto K., Iwata Y., Nakamura K., Tsujii M., Tsuchiya K., et al. Decreased serum levels of transforming growth factor-beta1 in patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:187-190.
87. Ashwood P., Anthony A., Torrente F., Wakefield A. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Clin Immunol 2004, 24:664-673.
88. Ashwood P., Wakefield A. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol 2006, 173:126-134.
89. Wei H., Zou H., Sheikh A., Malik M., Dobkin C., Brown W., et al. IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. J Neuroinflamm 2011, 8:52.
90. Morgan J., Chana G., Pardo C., Achim C., Semendeferi K., Buckwalter J., et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry 2010, 68:368-376.
91. Vargas D., Nascimbene C., Krishnan C., Zimmerman A., Pardo C. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005, 57:67-81.
92. Suzuki K., Sugihara G., Ouchi Y., Nakamura K., Futatsubashi M., Takebayashi K., et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry 2013, 70:49-58.
93. Ashwood P., Krakowiak P., Hertz-Picciotto I., Hansen R., Pessah I., Van de Water J. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J Neuroimmunol 2011, 232:196-199.
94. Al-Ayadhi L., Mostafa G. Elevated serum levels of macrophage-derived chemokine and thymus and activation-regulated chemokine in autistic children. J Neuroinflamm 2013, 10:72.
95. Kumar B., Prakash A., Sewal R., Medhi B., Modi M. Drug therapy in autism a present and future perspective. Pharmacol Rep 2012, 64:1291-1304.
96. Horvath K., Perman J. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep 2002, 4:251-258.
97. Angley M., Semple S., Hewton C., Paterson F., McKinnon R. Children and autism: Part 2 - management with complementary medicines and dietary interventions. Aust Fam Physician 2007, 36:827-830.
98. Choi J., Widjaja F., Careaga M., Bent S., Ashwood P., Hendren R. Change in plasma cytokine levels during risperidone treatment in children with autism. J Child Adolesc Psychopharmacol 2014, 24:1-4.
99. Asadabadi M., Mohammadi M., Ghanizadeh A., Modabbernia A., Ashrafi M., Hassanzadeh E., et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2013, 225:51-59.
100. Chez M., Guido-Estrada N. Immune therapy in autism historical experience and future directions with immunomodulatory therapy. Neurotherapeutics 2010, 7:293-301.